Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - PSYCHEMEDICS CORPFinancial_Report.xls
XML - IDEA: XBRL DOCUMENT - PSYCHEMEDICS CORPR8.htm
XML - IDEA: XBRL DOCUMENT - PSYCHEMEDICS CORPR1.htm
XML - IDEA: XBRL DOCUMENT - PSYCHEMEDICS CORPR7.htm
XML - IDEA: XBRL DOCUMENT - PSYCHEMEDICS CORPR9.htm
XML - IDEA: XBRL DOCUMENT - PSYCHEMEDICS CORPR2.htm
XML - IDEA: XBRL DOCUMENT - PSYCHEMEDICS CORPR3.htm
XML - IDEA: XBRL DOCUMENT - PSYCHEMEDICS CORPR6.htm
XML - IDEA: XBRL DOCUMENT - PSYCHEMEDICS CORPR22.htm
XML - IDEA: XBRL DOCUMENT - PSYCHEMEDICS CORPR18.htm
EX-31.1 - EXHIBIT 31.1 - PSYCHEMEDICS CORPv325709_ex31-1.htm
EX-32.1 - EXHIBIT 32.1 - PSYCHEMEDICS CORPv325709_ex32-1.htm
EX-32.2 - EXHIBIT 32.2 - PSYCHEMEDICS CORPv325709_ex32-2.htm
EX-31.2 - EXHIBIT 31.2 - PSYCHEMEDICS CORPv325709_ex31-2.htm
XML - IDEA: XBRL DOCUMENT - PSYCHEMEDICS CORPR4.htm
XML - IDEA: XBRL DOCUMENT - PSYCHEMEDICS CORPR5.htm
XML - IDEA: XBRL DOCUMENT - PSYCHEMEDICS CORPR11.htm
XML - IDEA: XBRL DOCUMENT - PSYCHEMEDICS CORPR21.htm
XML - IDEA: XBRL DOCUMENT - PSYCHEMEDICS CORPR13.htm
XML - IDEA: XBRL DOCUMENT - PSYCHEMEDICS CORPR10.htm
XML - IDEA: XBRL DOCUMENT - PSYCHEMEDICS CORPR16.htm
XML - IDEA: XBRL DOCUMENT - PSYCHEMEDICS CORPR19.htm
XML - IDEA: XBRL DOCUMENT - PSYCHEMEDICS CORPR12.htm
XML - IDEA: XBRL DOCUMENT - PSYCHEMEDICS CORPR15.htm
XML - IDEA: XBRL DOCUMENT - PSYCHEMEDICS CORPR14.htm
XML - IDEA: XBRL DOCUMENT - PSYCHEMEDICS CORPR20.htm
XML - IDEA: XBRL DOCUMENT - PSYCHEMEDICS CORPR23.htm
XML - IDEA: XBRL DOCUMENT - PSYCHEMEDICS CORPR17.htm

 


 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

Form 10-Q

 

xQuarterly report pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934

 

For the quarterly period ended September 30, 2012

 

or

 

¨Transition report pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934
  for the transition period from _________ to __________

 

Commission file number: 1-13738

 

PSYCHEMEDICS CORPORATION

(Exact Name of Registrant as Specified in its Charter)

 

Delaware   58-1701987
     
(State or Other Jurisdiction of   (I.R.S. Employer Identification No.)
Incorporation or Organization)    

 

125 Nagog Park    
Acton, MA   01720
     
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant's telephone number including area code: (978) 206-8220

 

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer (as defined in Rule 12b-2 of the Securities Exchange Act of 1934).

 

Large accelerated filer ¨ Accelerated filer ¨ Non-accelerated filer ¨ Smaller Reporting Company x
    (Do not check if smaller reporting Company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Securities Exchange Act of 1934). Yes £ No S

 

The number of shares of Common Stock of the Registrant, par value $0.005 per share, outstanding at November 9, 2012 was 5,272,428.

 

 
 

 

PSYCHEMEDICS CORPORATION

FORM 10-Q FOR THE QUARTER ENDED SEPTEMBER 30, 2012

 

INDEX

 

  Page
PART I - FINANCIAL INFORMATION  
   
Item 1 - Financial Statements (Unaudited)  
   
  Condensed Balance Sheets as of September 30, 2012 and December 31, 2011 3
  Condensed Statements of Income and Comprehensive Income for the Three and Nine months Ended September 30, 2012 and 2011 4
  Condensed Statements of Cash Flows for the Nine months Ended September 30, 2012 and 2011 5
  Notes to Condensed Financial Statements 6
     
Item 2 -     Management's Discussion and Analysis of Financial Condition and Results of Operations
     
  Overview 10
  Results of Operations 11
  Liquidity and Capital Resources 12
  Critical Accounting Policies and Estimates 14
     
Item 3 - Quantitative and Qualitative Disclosures About Market Risk 14
   
Item 4 - Controls and Procedures 14
     
PART II - OTHER INFORMATION  
   
Item 1A - Risk Factors 15
Item 2 - Unregistered Sales of Equity Securities and Use of Proceeds 15
Item 6 - Exhibits 15
   
Signatures 15
   
Exhibit Index 16

 

2
 

 

PSYCHEMEDICS CORPORATION

CONDENSED BALANCE SHEETS

(UNAUDITED) 

 

   September 30,   December 31, 
   2012   2011 
         
ASSETS          
Current Assets:          
Cash and cash equivalents  $3,663,499   $5,564,233 
Accounts receivable, net of allowance for doubtful accounts of $131,218 in 2012 and $169,191 in 2011   5,343,338    4,490,976 
Prepaid expenses and other current assets   1,093,408    565,508 
Income tax receivable   --    564,083 
Deferred tax assets   451,681    315,501 
           
Total Current Assets   10,551,926    11,500,301 
Fixed Assets, net of accumulated amortization and depreciation of $4,222,467 in 2012 and $11,026,278 in 2011   3,490,382    2,063,377 
           
Other assets   309,717    237,174 
           
Total Assets  $14,352,025   $13,800,852 
           
LIABILITIES AND SHAREHOLDERS' EQUITY          
           
Current Liabilities:          
Accounts payable  $1,266,603   $961,844 
Accrued expenses   984,465    1,321,856 
           
Total Current Liabilities   2,251,068    2,283,700 
           
Deferred tax liabilities, long-term   482,523    482,523 
Total Liabilities   2,733,591    2,766,223 
           
Commitments and Contingencies (Note 7)          
Shareholders' Equity:          
Preferred-stock, $0.005 par value, 872,521 shares authorized, no shares issued or outstanding   --    -- 
Common stock, $0.005 par value; 50,000,000 shares authorized 5,940,558 shares issued in 2012 and 5,903,552 shares issued 2011   29,703    29,518 
Additional paid-in capital   28,338,280    28,095,946 
Accumulated deficit   (6,667,760)   (7,009,046)
Less - Treasury stock, at cost, 668,130 shares   (10,081,789)   (10,081,789)
           
Total Shareholders' Equity   11,618,434    11,034,629 
           
Total Liabilities and Shareholders' Equity  $14,352,025   $13,800,852 

 

See accompanying notes to condensed financial statements

 

3
 

 

PSYCHEMEDICS CORPORATION

CONDENSED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME

(UNAUDITED)

 

   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2012   2011   2012   2011 
                 
Revenues  $6,459,775   $6,315,142   $19,565,350   $18,542,666 
Cost of revenues   2,742,072    2,371,255    8,079,141    7,243,474 
                     
Gross profit   3,717,703    3,943,887    11,486,209    11,299,192 
                     
Operating Expenses:                    
General & administrative   921,891    1,018,967    2,921,880    2,898,426 
Marketing & selling   1,067,768    981,197    3,413,388    2,945,492 
Research & development   297,090    136,281    679,031    399,785 
                     
Total Operating Expenses   2,286,749    2,136,445    7,014,299    6,243,703 
                     
Operating income   1,430,954    1,807,442    4,471,910    5,055,489 
Interest income   447    773    1,442    4,790 
                     
Net income before provision for income taxes   1,431,401    1,808,215    4,473,352    5,060,279 
                     
Provision for income taxes   552,920    708,830    1,766,336    2,009,184 
                     
Net income and comprehensive income  $878,481   $1,099,385   $2,707,016   $3,051,095 
                     
Basic net income per share  $0.17   $0.21   $0.52   $0.58 
                     
Diluted net income per share  $0.17   $0.21   $0.51   $0.58 
                     
Dividends declared per share  $0.15   $0.12   $0.45   $0.36 
                     
Weighted average common shares outstanding, basic   5,272,428    5,237,603    5,256,240    5,227,699 
                     
Weighted average common shares outstanding, diluted   5,289,808    5,240,895    5,266,237    5,234,577 

 

See accompanying notes to condensed financial statements

 

4
 

 

PSYCHEMEDICS CORPORATION

CONDENSED STATEMENTS OF CASH FLOWS

(UNAUDITED)

 

   Nine Months Ended 
   September 30, 
   2012   2011 
         
CASH FLOWS FROM OPERATING ACTIVITIES:          
Net income  $2,707,016   $3,051,095 
           
Adjustments to reconcile net income to net cash provided by operating activities:          
Depreciation and amortization   419,541    258,708 
Stock-based compensation   337,078    304,408 
Deferred income taxes   (136,180)   (122,322)
Changes in operating assets and liabilities:          
Accounts receivable   (852,362)   (2,291,612)
Prepaid expenses, other current assets, and income tax receivable   36,183    (135,247)
Accounts payable   304,759    (405,903)
Accrued expenses   (337,391)   138,616 
Deferred revenue   -    (16,605)
Net cash provided by operating activities   2,478,644    781,138 
           
CASH FLOWS USED IN INVESTING ACTIVITIES:          
Purchases of short-term investments   -    (13,198,341)
Sales of short-term investments   -    15,216,793 
Purchases of equipment and leasehold improvements   (1,837,200)   (912,620)
Other assets   (81,889)   (113,939)
Net cash (used in) provided by investing activities   (1,919,089)   991,893 
           
CASH FLOWS USED IN FINANCING ACTIVITIES:          
Proceeds from issuance of stock, net of tax withholding   (94,559)   (86,992)
Acquisition of treasury stock   -    (22,391)
Cash dividends paid   (2,365,730)   (1,882,611)
Net cash used in financing activities   (2,460,289)   (1,991,994)
           
Net decrease in cash   (1,900,734)   (218,963)
           
Cash and Cash Equivalents, beginning of period   5,564,233    3,720,488 
Cash and Cash Equivalents, end of period  $3,663,499   $3,501,525 
           
Supplemental Disclosures of Cash Flow Information:          
Cash paid for income taxes  $1,208,800   $1,729,000 

 

See accompanying notes to condensed financial statements

 

5
 

 

PSYCHEMEDICS CORPORATION

NOTES TO CONDENSED FINANCIAL STATEMENTS

(UNAUDITED)

 

1.Interim Financial Statements

 

The accompanying unaudited interim financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission for reporting on Form 10-Q. Accordingly, certain information and footnote disclosure required for complete financial statements are not included herein. It is recommended that these financial statements be read in conjunction with the financial statements and related notes of Psychemedics Corporation (“the Company,” “our Company,” “our” or “we”) as reported in the Company’s Annual Report on Form 10-K for the year ended December 31, 2011, filed on March 9, 2012. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of financial position, results of operations, and cash flows at the dates and for the periods presented have been included. The results of operations for the nine months ended September 30, 2012 may not be indicative of the results that may be expected for the year ending December 31, 2012, or any other period.

 

2.Cash and Cash Equivalents

 

The Company considers all highly liquid investments with original maturities of 90 days or less to be cash equivalents. Cash equivalents consist of cash savings and a bank money market account.

 

3.Stock-Based Compensation

 

2006 Equity Incentive Plan

The Company’s 2006 Incentive Plan provides for the grant or issuance to officers, directors, employees and consultants of options with terms of up to ten years, restricted stock, stock unit awards (SUA’s), issuances of stock bonuses or other stock-based awards, covering up to 500,000 shares of common stock.

 

The Company granted stock unit awards (SUAs) covering 65,000 shares of common stock on May 22, 2012. There were no previously granted awards that terminated during the first nine months of 2012. The SUAs vest over a period of two years for non-employee board members and four years for employees and are convertible into an equivalent number of shares of the Company’s common stock provided that the director or employee receiving the award remains continuously employed throughout the vesting period. The Company records compensation expense related to the SUAs on a straight-line basis over the vesting term of the SUAs. Employees are issued shares upon vesting, net of tax withholdings, unless the employee chooses to receive shares and pay for the associated employment taxes. No other types of equity-based awards have been granted or issued under the 2006 Incentive Plan.

 

6
 

 

PSYCHEMEDICS CORPORATION

NOTES TO CONDENSED FINANCIAL STATEMENTS

(UNAUDITED)

 

3.Stock-Based Compensation (continued)

A summary of activity for SUAs under the Company’s 2006 Incentive Plan for the nine months ended September 30, 2012 is as follows:

 

   Number
of
Shares
   Aggregate
Intrinsic
Value (1)
 
       (000s) 
Unvested, December 31, 2011   119,100      
Granted   65,000      
Shares withheld for taxes   (9,619)     
Converted to common stock   (37,006)     
Unvested, September 30, 2012   137,475   $1,659 
Available for grant, September 30, 2012   220,069      

 

(1)The aggregate intrinsic value on this table was calculated based on the closing market value of the Company’s stock on September 30, 2012 ($12.07).

 

Expired Plans

As of September 30, 2012, the Company also had outstanding an aggregate of 199,838 options to acquire common stock under plans that had previously expired. A summary of stock option activity for the Company’s expired stock option plans for the nine months ended September 30, 2012 is as follows:

 

   Number
of
Shares
    Weighted
Average
Exercise
Price Per
Share
    Weighted
Average
Remaining
Contractual
Life
    Aggregate
Intrinsic
Value (2)
 
                   (000s)
Outstanding, December 31, 2011   221,239   $13.62           
Granted   -    -           
Exercised   -    -    -      
Terminated/Expired   (21,401)  $13.66       
Outstanding, September 30, 2012   199,838   $13.62    2.4 years   $60 
Exercisable, September 30, 2012   199,838   $13.62    2.4 years   $60 
Available for grant, September 30, 2012   -                

 

(2)The aggregate intrinsic value on this table was calculated based on the amount, if any, by which the closing market value of the Company’s stock on the September 30, 2012 ($12.07) exceeded the exercise price of the underlying options, multiplied by the number of shares subject to each option.

 

7
 

 

PSYCHEMEDICS CORPORATION

NOTES TO CONDENSED FINANCIAL STATEMENTS

(UNAUDITED)

 

3.Stock-Based Compensation (continued)

 

All Stock-Based Compensation Plans

As of September 30, 2012, a total of 557,382 shares of common stock were reserved for issuance under the various stock option and stock-based plans. As of September 30, 2012, the unamortized fair value of awards relating to outstanding SUAs and options was $1.1 million, which is expected to be amortized over a weighted average period of 3.0 years.

 

4.Basic and Diluted Net Income Per Share

 

Basic net income per share is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per share is computed by dividing net income by the weighted average number of common and dilutive common equivalent shares outstanding during the period. The number of dilutive common equivalent shares outstanding during the period has been determined in accordance with the treasury-stock method. Common equivalent shares consist of common stock issuable upon the exercise of outstanding options and common stock issuable upon the vesting of outstanding, unvested SUAs.

 

Basic and diluted weighted average common shares outstanding are as follows:

 

   Three Months Ended   Nine Months Ended 
   September
30,
   September
30,
   September
30,
   September
30,
 
   2012   2011   2012   2011 
   (in thousands) 
                 
Weighted average common shares   5,272    5,238    5,256    5,228 
Common equivalent shares   18    3    10    7 
Weighted average common shares outstanding, assuming dilution   5,290    5,241    5,266    5,235 

 

For the three months ended September 30, 2012 and 2011, options to purchase 231 thousand and 269 thousand common shares, respectively, were outstanding but not included in the diluted weighted average common share calculation as the effect would have been antidilutive. The amounts for the nine month period ended September 30, 2012 and 2011 were 264 thousand and 265 thousand common shares, respectively.

 

8
 

 

PSYCHEMEDICS CORPORATION

NOTES TO CONDENSED FINANCIAL STATEMENTS

(UNAUDITED)

 

5.Fair Value Measurements

 

ASC 820, Fair Value Measurements and Disclosures, provides guidance for using fair value to measure assets and liabilities. It also responds to investors’ requests for expanded information about the extent to which companies’ measure assets and liabilities at fair value, the information used to measure fair value, and the effect of fair value measurements on earnings. ASC 820 applies whenever other standards require (or permit) assets or liabilities to be measured at fair value, and does not expand the use of fair value in any new circumstances.

 

It establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy prioritizes the inputs in three broad levels as follows:

 

·Level 1 inputs are unadjusted quoted prices in active markets that are accessible at the measurement date for identical assets and liabilities.
·Level 2 inputs are quoted prices for similar assets and liabilities in markets that are not active or for which all significant inputs are observable, either directly or indirectly.
·Level 3 inputs are prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.

 

A financial asset’s or liability’s classification within the hierarchy is determined based on the lowest level of any input that is significant to the fair value measurement.

 

The financial assets of the Company measured at fair value on a recurring basis are cash and cash equivalents. The Company’s cash equivalents are classified within level 1 of the fair value hierarchy because they are valued using quoted market prices that are accessible at the measurement date for identical assets and liabilities. The cash equivalents were $3.7 million as of September 30, 2012 and $5.6 million as of December 31, 2011.

 

6.Subsequent Events

 

On November 5, 2012, the Company declared a quarterly dividend of $0.15 per share for a total of $791 thousand, which will be paid on November 28, 2012 to shareholders of record on November 15, 2012.

 

7.Commitments and Contingencies

 

The Company is subject to legal proceedings and claims, which arise in the ordinary course of its business. The Company believes that based upon information available to the Company at this time, the expected outcome of these matters would not have a material impact on the Company’s results of operations or financial condition.

   

8.Fixed Asset Disposals

 

During the quarter, primarily in connection with the transition of the Company’s RIAH technology to EIA technology, the Company disposed of approximately $7.2 million of fixed assets.  These assets had a net book value of zero at the time of disposal.

 

9
 

 

Item 2.

 

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

FACTORS THAT MAY AFFECT FUTURE RESULTS

 

From time to time, information provided by the Company or statements made by its employees may contain "forward-looking" information which involves risks and uncertainties. In particular, statements contained in this report which are not historical facts (including, but not limited to, the Company's expectations regarding earnings, earnings per share, revenues, operating cash flows, dividends, future business, growth opportunities, new accounts, customer base, test volume, sales and marketing strategy, business strategy, general and administrative expenses, marketing and selling expenses, research and development expenses, anticipated operating results, strategies with respect to governmental agencies and regulations, cost savings, capital expenditures, liquidity of investments and anticipated cash requirements) may be "forward-looking" statements. The Company's actual results may differ from those stated in any "forward-looking" statements. Factors that may cause such differences include, but are not limited to, risks associated with the expansion of the Company’s sales and marketing team, employee hiring practices of the Company’s principal customers, development of markets for new products and services offered by the Company, the economic health of principal customers of the Company, global credit market volatility, financial and operational risks associated with possible expansion of testing facilities used by the Company, government regulation (including, but not limited to, Food and Drug Administration regulations), competition and general economic conditions. With respect to the continued payment of cash dividends, factors include, but are not limited to, available surplus, cash flow, capital expenditure reserves required, and other factors that the Board of Directors of the Company may take into account.

 

OVERVIEW

Psychemedics Corporation was incorporated in 1986. The Company is the world’s largest provider of hair testing for drugs of abuse, utilizing a patented hair analysis method involving immunoassay technology and confirmation by mass spectrometry to analyze human hair to detect abused substances. The Company’s customers include Fortune 500 companies, as well as small to mid-size corporations, schools and governmental entities located primarily in the United States. During the third quarter of 2012, the Company made a transition in hair testing technology from radioimmonoassy (RIAH) to a custom designed enzyme immunoassay (EIA). The financial impact on the third quarter results is included in the discussion below.

 

Revenues for the third quarter of 2012 were $6.5 million, an increase of 2% from the third quarter 2011 revenue of $6.3 million. The Company reported net income of $0.17 per diluted share for the three months ended September 30, 2012, compared to net income of $0.21 per share in the comparable period in 2011. At September 30, 2012, the Company had $3.7 million of cash and cash equivalents. The Company distributed $791 thousand or $0.15 per share of cash dividends to its shareholders in the three months ended September 30, 2012. The Company has paid sixty-four consecutive quarterly cash dividends.

 

10
 

 

RESULTS OF OPERATIONS

 

Revenues were $6.5 million for three months ended September 30, 2012 compared to revenues of $6.3 million for the three months ended September 30, 2011, representing an increase of 2%. The increase in revenues for the three months ended September 30, 2012 was a result of an increase in testing volume from new and existing clients of 5%. The average revenue per sample decreased 3% from the comparative period of 2011, which was primarily driven by the mix of customers. Revenues for the nine months ended September 30, 2012 were $19.6 million, representing an increase of 6% in revenues from the comparable period of 2011 of $18.5 million. The increase was primarily due to an increase in volume, as test samples increased 8% from the first nine months of 2011.

 

Gross profit was $3.7 million and $3.9 million for the three months ended September 30, 2012 and September 30, 2011, respectively. Direct costs increased by $370 thousand or 16% for the three months ended September 30, 2012 compared to the same period of 2011, due to a greater volume of samples and transition costs from our hair testing technology of RIAH to EIA. During the quarter, the Company capitalized $298 thousand of software development costs related to the new EIA process, $137 thousand of which was incurred in the third quarter, and $161 thousand which had been expensed in the first six months of 2012. The gross profit margin for the three month period ended September 30, 2012 was 58% compared to 62% for the comparable period in 2011. Gross profit for the nine months ended September 30, 2012 increased $187 thousand to $11.5 million compared to $11.3 million for the comparable period in 2011. Direct costs increased by $835 thousand or 12% for the nine months ended September 30, 2012 when compared to the same period in 2011, mostly due to a greater volume in samples and partly due to transition costs from RIAH to EIA. The gross profit margin for the nine month period ended September 30, 2012 was 59% compared to 61% for the comparable period in 2011.

 

General and administrative (“G&A”) expenses were $922 thousand and $1.0 million for the three months ended September 30, 2012 and 2011, respectively. As a percentage of revenue, G&A expenses were 14% and 16% for the three months ended September 30, 2012 and 2011, respectively. General and administrative expenses were $2.9 million for the nine months ended September 30, 2012 and 2011. As a percentage of revenue, G&A expenses were 15% and 16% for the nine months ended September 30, 2012 and 2011, respectively.

 

Marketing and selling expenses were $1.1 million for the three months ended September 30, 2012 as compared to $981 thousand for the three months ended September 30, 2011, an increase of 9%. Total marketing and selling expenses represented 17% of revenue for the three months ended September 30, 2012, compared to 16% for the comparable period of 2011. For the nine months ended September 30, 2012, marketing and selling expenses were $3.4 million, an increase of $468 thousand from the prior year at $2.9 million. The increase in marketing and selling expenses was primarily from additional sales positions, as well as higher information technology costs related to marketing programs.

 

11
 

 

Research and development (“R&D”) expenses for the three months ended September 30, 2012 were $297 thousand compared to $136 thousand for the comparable period of 2011, an increase of 118%. This increase is driven by R&D activities related to EIA analysis. R&D expenses represented 5% of revenue for the three months ended September 30, 2012, compared to 2% for the comparable period of 2011. Research and development expenses for the nine months ended September 30, 2012 were $679 thousand compared to $400 thousand in the prior year. R&D expenses represented 3% and 2% of revenue for the nine months ended 2012 and 2011, respectively.

 

Provision for income taxes During the three months ended September 30, 2012 and 2011, the Company recorded tax provisions of $553 thousand and $709 thousand, respectively. These provisions represented effective tax rates of 39% for the three months ended September 30, 2012 and for the comparable period of 2011. During the nine months ended September 30, 2012 and September 30, 2011, the Company recorded tax provisions of $1.8 million and $2.0 million, respectively. These provisions represented effective tax rates of 39% and 40% for the nine month periods ended September 30, 2012 and 2011, respectively. The 39% represents the current estimate of the year-end tax rate. The Company continues to monitor the effective tax rate, but does not expect a significant change for the remaining three months of 2012. 

 

LIQUIDITY AND CAPITAL RESOURCES

 

At September 30, 2012, the Company had approximately $3.7 million of cash and cash equivalents. The Company's operating activities provided net cash of $2.5 million for the nine months ended September 30, 2012. Investing activities used $1.9 million of cash while financing activities (primarily dividends) used $2.5 million of cash during the first nine months of 2012.

 

Cash provided by operating activities of $2.5 million reflected net income of $2.7 million adjusted for depreciation and amortization of $419 thousand, stock-based compensation of $337 thousand, and a decrease for deferred income taxes of $136 thousand. This was affected by the following changes in assets and liabilities: an increase in accounts receivable of $852 thousand, a decrease in prepaid expenses and other current assets of $36 thousand, an increase in accounts payable of $305 thousand, and a decrease in accrued expenses of $337 thousand.

 

Cash used in investing activities included equipment and leasehold improvements of $1.9 million which were purchased during the nine months of 2012. We anticipate spending $400 thousand to $700 thousand in additional capital purchases for the remainder of 2012.

 

During the nine months ended September 30, 2012, the Company distributed $2.4 million in cash dividends to its shareholders.

 

12
 

 

Contractual obligations as of September 30, 2012 were as follows:

 

   Less Than
One Year
   1-3
Years
   4-5
years
   After 5
Years
   Total 
   (in thousands) 
Operating leases  $608   $1,163   $156   $-   $1,927 
Purchase commitment   266    -    -    -    266 
   $874   $1,163   $156   $-   $2,193 

 

In May 2012, the Company extended the lease of its Las Vegas facility for four years, to expire in April, 2016. This extension is reflected in the prior table. The Company has a supply agreement with a vendor which requires the Company to purchase isotopes used in its radioimmunoassay drug testing procedures from this sole supplier in exchange for variable annual payments based upon prior calendar year purchases. Purchases amounted to $457 thousand for the nine months ended September 30, 2012 as compared to $396 thousand for the comparable period of 2011. The Company expects to expend approximately $152 thousand for isotope purchases during the remainder of 2012. As of October 1st, 2012, the Company has given its six month notice to terminate the isotope agreement in conjunction with the change from radioimmunoassay technology to enzyme immunoassay technology. 

 

At September 30, 2012, the Company's principal sources of liquidity included an aggregate of approximately $3.7 million of cash and cash equivalents. Management currently believes that such funds, together with cash generated from operations, should be adequate to fund anticipated working capital requirements and capital expenditures for at least the next 12 months. Depending upon the Company's results of operations and capital needs, the Company may use various financing sources to raise additional funds, although the Company does not have any such plans at this time. At September 30, 2012, the Company had no long-term debt.

 

13
 

 

CRITICAL ACCOUNTING POLICIES

 

In our Annual Report on Form 10-K for the year ended December 31, 2011, filed on March 9, 2012, we disclosed our critical accounting policies and estimates upon which our financial statements are derived. There have been no changes to these policies since December 31, 2011. Readers are encouraged to review these disclosures in conjunction with the review of this quarterly report on Form 10-Q.

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk

 

Interest Rate Sensitivity. The Company maintains cash and cash equivalents which consist of cash and money market funds with financial institutions. Due to the conservative nature and relatively short duration of our cash and cash equivalents interest rate risk is mitigated.

 

Based on our ability to access our cash and cash equivalents, our expected operating cash flows and our other sources of cash; we do not anticipate that any lack of liquidity will materially affect our ability to operate our business.

 

Item 4. Controls and Procedures

 

As of the date of this report, our Chief Executive Officer and our Vice President - Finance performed an evaluation of the effectiveness of the design and operation of the Company’s disclosure controls and procedures pursuant to Exchange Act Rule 13a-14. Based upon that evaluation, the Chief Executive Officer and Vice President - Finance concluded that the Company’s disclosure controls and procedures were effective for ensuring that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act of 1934 is recorded, processed, summarized and disclosed within the time periods specified in the SEC’s rules and forms, and that its disclosure controls and procedures were also effective to ensure that information required to be disclosed in the reports that it files or submits under the Exchange Act is accumulated and communicated to management, including the Company’s principal executive and principal financial officers, to allow timely decisions regarding required disclosure. There were no significant changes in the Company’s internal controls over financial reporting or in other factors that could significantly affect these internal controls over financial reporting subsequent to the date of the most recent evaluation.

 

14
 

 

PART II OTHER INFORMATION

 

Item 1A. Risk Factors

 

There have been no material changes in our risk factors from those disclosed in our 2011 Annual Report on Form 10-K.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

None.

 

Item 6. Exhibits

 

See Exhibit Index included in this Report

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Psychemedics Corporation
   
Date:          November 9, 2012
  By: /s/ Raymond C. Kubacki
  Raymond C. Kubacki
  Chairman and Chief Executive Officer
  (principal executive officer)
   
Date:          November 9, 2012
  By: /s/ Neil L. Lerner
  Neil L. Lerner
  Vice President - Finance
  (principal accounting officer)

 

15
 

 

PSYCHEMEDICS CORPORATION

FORM 10-Q

September 30, 2012

EXHIBIT INDEX

 

    Page No.
31.1

Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

17
     
31.2

Certification of Principal Accounting Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

18
     
32.1

Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

19
     
32.2

Certification of Principal Accounting Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

20

 

16